Table 1.
Cases of CNL in which both cytogenetic and molecular clonal evolutions were evaluated.
| Case | Reporter | Age (years)/Sex | Stage | CSF3R | SETBP1 | ASXL1 | SRSF2 | CBL | Other mutated genes | Cytogenetics | Survival (months) |
| 1 | Fathi et al. [6] | 86/F | Dx | T618I (28%) | D868N (40%) | H633fs* (24%) | WT | WT | TET2 D143fs* (40%), TP53 R273H (6%) | 46,XX | 17 |
| CLL | T618I in the CD19− cells | D868N in the CD19− cells | H633fs* in the CD19− cells | WT | WT | TET2 in the CD19− cells, TP53 in the CD19+ cells | der(6;17)(p10;q10) | ||||
| 2 | Nooruddin et al. [8] | 69/M | Dx | T618I (36%) | G870S (45%) | WT | WT | WT | RUNX1 337_341del (5%) | 46,Y,t(X;7)(p22.1;q36) [20/20] | 9 |
| progression | T618I (7%) | G870S (6%) | WT | WT | WT | RUNX1 337_341del (39%), GATA2 K392fs (37%),KIT D816V (34%) | 46,Y,t(X;7)(p22.1;q36) [20/20] | ||||
| 3 | Langabeer et al. [5] | 60/F | Dx | T618I (38%) | D868N (42%) | WT | P95H (41%) | G415S (15%) | 46,XX [17] | 25 | |
| AML | T618I (51%) | D868N (48%) | WT | P95H (51%) | WT | 47,XX,+19 [2]/46,XX [5] | |||||
| 4 | Langabeer et al. [5] | 66/M | Dx | T618I (38%) | D868N (36%) | WT | P95H (37%) | WT | 46,XY [20] | 36 | |
| AML | T618I (77%) | D868N (39%) | WT | P95H (46%) | WT | NRAS G13C (30%) | 46,XY,add(12)(p11.2) [9]/46,XY [1] | ||||
| 5 | Present case | 55/M | Dx | T618I (50%) | WT | WT | WT | WT | 46,XY [20/20] | 37 | |
| AML | T618I (50%) | I871T (69%) | WT | WT | WT | t(4;12)(q12; p13) [19/20]/46,XY [1/20] |
M male, F female, Dx diagnosis, WT wild type, CLL chronic lymphocytic leukemia, AML acute myeloid leukemia.